Literature DB >> 1730520

Establishment and characterization of a thymic carcinoma cell line (Ty-82) carrying t(15;19)(q15;p13) chromosome abnormality.

T Kuzume1, I Kubonishi, S Takeuchi, T Takeuchi, J Iwata, H Sonobe, Y Ohtsuki, I Miyoshi.   

Abstract

A new human cell line, designated Ty-82, was established from the pleural effusion of a 22-year-old woman with undifferentiated thymic carcinoma. This cell line consisted of primitive cells that were positive for alpha-naphthyl butyrate esterase and acid phosphatase. The cells were shown to express epithelial membrane antigen, but were completely negative for cytokeratin, carcinoembryonic antigen, glial fibrillary acidic protein, desmin, S-100 protein, lysozyme, Leu-7, HLA-DR (Ia), leukocyte common antigen, Ki-I antigen, T-cell antigens, B-cell antigens, myelomonocyte antigens, and Epstein-Barr-virus nuclear antigen. Electron microscopy showed that the cells were highly anaplastic, with no sign of cellular differentiation to any lineages. The Ty-82 cell line was found to have a karyotype of 46,XX,t(15;19)(q15;p13), being identical to that of the patient's tumor cells. Four of 5 nude mice inoculated sub-cutaneously with Ty-82 cells developed tumors which displayed a histological picture similar to the original tumor. Thymic carcinoma is a recently recognized entity, and its cellular and clinical behavior are poorly understood. The newly established thymic carcinoma cell line would provide a useful tool for the better understanding of this rare disease.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1730520     DOI: 10.1002/ijc.2910500216

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  11 in total

1.  BRD4 bromodomain gene rearrangement in aggressive carcinoma with translocation t(15;19).

Authors:  C A French; I Miyoshi; J C Aster; I Kubonishi; T G Kroll; P Dal Cin; S O Vargas; A R Perez-Atayde; J A Fletcher
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  NUT rearrangement is uncommon in human thymic epithelial tumors.

Authors:  Petrini Petrini; Christopher A French; Arun Rajan; Michael J Cameron; Elaine S Jaffe; Paolo A Zucali; Jianwu Xie; Yisong Wang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2012-04       Impact factor: 15.609

3.  Differentiation of NUT midline carcinoma by epigenomic reprogramming.

Authors:  Brian E Schwartz; Matthias D Hofer; Madeleine E Lemieux; Daniel E Bauer; Michael J Cameron; Nathan H West; Elin S Agoston; Nicolas Reynoird; Saadi Khochbin; Tan A Ince; Amanda Christie; Katherine A Janeway; Sara O Vargas; Antonio R Perez-Atayde; Jon C Aster; Stephen E Sallan; Andrew L Kung; James E Bradner; Christopher A French
Journal:  Cancer Res       Date:  2011-03-29       Impact factor: 12.701

Review 4.  NUT midline carcinoma.

Authors:  Christopher Alexander French
Journal:  Cancer Genet Cytogenet       Date:  2010-11

5.  Activation of SOX2 expression by BRD4-NUT oncogenic fusion drives neoplastic transformation in NUT midline carcinoma.

Authors:  Ranran Wang; Wei Liu; Christine M Helfer; James E Bradner; Jason L Hornick; Susan M Janicki; Christopher A French; Jianxin You
Journal:  Cancer Res       Date:  2014-04-15       Impact factor: 12.701

6.  PI3K as a Potential Therapeutic Target in Thymic Epithelial Tumors.

Authors:  Anna Teresa Alberobello; Yisong Wang; Frans Joseph Beerkens; Fabio Conforti; Justine N McCutcheon; Guanhua Rao; Mark Raffeld; Jing Liu; Raneen Rahhal; Yu-Wen Zhang; Giuseppe Giaccone
Journal:  J Thorac Oncol       Date:  2016-04-24       Impact factor: 15.609

7.  Establishment and characterization of a novel cell line derived from thymoma with myasthenia gravis patients.

Authors:  Guojin Wang; Yuanguo Wang; Peng Zhang; Yuan Chen; Yimei Liu; Feng Guo; Hui Zhang
Journal:  Thorac Cancer       Date:  2015-03-02       Impact factor: 3.500

8.  Complex chromosomal rearrangements by single catastrophic pathogenesis in NUT midline carcinoma.

Authors:  J-K Lee; S Louzada; Y An; S Y Kim; S Kim; J Youk; S Park; S H Koo; B Keam; Y K Jeon; J-L Ku; F Yang; T M Kim; Y S Ju
Journal:  Ann Oncol       Date:  2017-04-01       Impact factor: 32.976

9.  Molecular-genetic profiling and high-throughput in vitro drug screening in NUT midline carcinoma-an aggressive and fatal disease.

Authors:  Anja Stirnweiss; Joyce Oommen; Rishi S Kotecha; Ursula R Kees; Alex H Beesley
Journal:  Oncotarget       Date:  2017-12-02

10.  miR-3140 suppresses tumor cell growth by targeting BRD4 via its coding sequence and downregulates the BRD4-NUT fusion oncoprotein.

Authors:  Erina Tonouchi; Yasuyuki Gen; Tomoki Muramatsu; Hidekazu Hiramoto; Kousuke Tanimoto; Jun Inoue; Johji Inazawa
Journal:  Sci Rep       Date:  2018-03-14       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.